PHARMASHOTS NEWSWIRE

 One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries – – Both Applications Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline Based on Potential Public Health Int

Summit and Pfizer Seek to Accelerate Development Opportunities of Ivonescimab and Vedotin-based ADCs Pfizer to Contribute Multiple ADCs to Evaluate with Ivonescimab in Unique Solid Tumor Settings Clinical Trials Expected to Start in the Middle of This Year February 24, 2025 06:00 AM Eastern

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated in the trial TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) --&n

Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in US Strengthens US immunology portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in just one shot.  H5 avian influenza is a highly contagious and notifiable zoonotic disease, that is currently having a he

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult